Integrating New Data on HIV Adverse Events From IAS 2023: Pharmacist Perspectives

In this episode, Brooke Bates, PharmD, BCPS, AAHIVP, and Neha Sheth Pandit, PharmD, AAHIVP, BCPS, discuss the most clinically relevant studies on HIV adverse events presented at IAS 2023, including: REPRIEVE study of pitavastatin for cardiovascular prevention in people living with HIV at low to moderate cardiovascular riskData on weight change with switch from integrase inhibitor–based ART to doravirine/islatravir in the P017 and P018 studiesDEFINE study evaluating weight change after a switch to DRV/COBI/FTC/TAF in people living with HIV who experienced weight gain with integrase inhibitor–based ARTFaculty: Brooke Bates, PharmD, BCPS, AAHIVP<br />Specialty Pharmacy Clinical Manager <br />Pediatric HIV Clinical Pharmacist<br />Indiana University Health<br />Indianapolis, IndianaNeha Sheth Pandit, PharmD, AAHIVP, BCPS<br />Professor<br />Vice Chair for Research and Scholarship<br />Department of Practice, Sciences, and Health Outcomes Research<br />School of Pharmacy<br />University of Maryland <br />Clinical Pharmacist<br />THRIVE Program<br />Baltimore, MarylandLink to full program: <br />https://bit.ly/3ZjSFhg